QNRX - Earnings announcements

-  Positive 6 Month Clinical Data Reported for Ongoing Pediatric Netherton Syndrome Study -  FDA Clears Second Pivotal Study of QRX003 for Netherton Syndrome -  Initial Positive Data Announced from Peeling Skin Syndrome Pediatric Study -  Orphan Drug Designation Granted by European Medicines Agency for QRX003 -  Rare Pediatric Disease Designation Awarded by U.S. FDA -  NETHERTON NOW Campaign Expanded with New Patient and Expert Video Releases ASHBURN, Va., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases provided a corporate upda

Continued Progress in Ongoing Late-Stage Netherton Syndrome Studies Announced Positive Clinical Data for Adult and Pediatric Netherton Patients Provided Clear Visual Evidence of QRX003 Mechanism of Action Patent Portfolio Expanded to Support Pipeline GrowthLaunch of NETHERTON NOW Advocacy Initiative ASHBURN, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the quarter ended March 31, 2025. Quoin CEO Dr. Michael Myers

Quoin Initiates Peeling Skin Syndrome Clinical Program Further Expansion of International Reach for Netherton Syndrome Clinical Trials Significant Insider Share Purchases by the Entire Management Team ASHBURN, Va., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical-stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the three and nine months ended Sept. 30, 2024. Quoin CEO Dr. Michael Myers said, "The third quarter has been marked by notable achievements, including expanding the c

Quoin Broadens Product Portfolio through Research Agreement with University College Cork, Ireland Company Expands On-going Clinical Trials in Netherton Syndrome to Include International Sites Announced Plans to Initiate Clinical Study in Peeling Skin Syndrome Continues to Evaluate M&A Opportunities in Rare and Orphan Diseases ASHBURN, Va., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the three and six months ended June 30,

ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its fourth quarter and 2023 financial results after the market closes on Wednesday, March 13, 2024. The Company will host a conference call and webcast at 8:30am ET on Thursday, March 14, 2024.   The call will include a discussion of fourth quarter and 2023 financial results and a corporate update.   The live call can be accessed by dialing 1-800-603-0527 (domestic) or 1-412-317-0688 (international). The live and archived webcast of the

Company reported positive clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study Positive benefits were observed across a number of clinical endpoints including pruritus, Investigator skin scoring system and patient global assessment No safety concerns have been observed to date in either ongoing clinical study Quoin expects its cash runway will extend through the end of 2024 ASHBURN, Va., Nov. 08, 2023 (GLOBE NEWSWIRE) --  Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today provides a business update and announces financial r

ASHBURN, Va., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its third quarter 2023 financial results after the market closes on Wednesday, November 8, 2023. The Company will host a conference call and webcast at 8:30am ET on Thursday, November 9, 2023.   The call will include a discussion of third quarter 2023 financial results and a corporate update.   The live call can be accessed by dialing 1-800-603-0527 (domestic) or 1-412-317-0688 (international). The live and archived webcast of the call w

Company reports positive clinical data for first subject to complete testing in ongoing open-label Netherton Syndrome study Subject's skin was assessed to be fully clear by Investigator at QRX003 treatment areas Subject also demonstrated key improvements across all other clinical endpoints, including pruritis A majority of patients in both Netherton Syndrome studies are expected to be enrolled by the end of August Both studies are demonstrating an exemplary safety profile for QRX003 Quoin expects its cash runway will extend well into 2H 2024 ASHBURN, Va., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage, specialty

ASHBURN, Va., July 27, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its second quarter 2023 financial results after the market closes on Wednesday, August 2, 2023. The Company will host a conference call and webcast at 8:30am ET on Thursday, August 3, 2023. The call will include a discussion of second quarter 2023 financial results and a corporate update. The live call can be accessed by dialing 1-800-603-0527 (domestic) or 1-412-317-0688 (international). The live and archived webcast of the call will al

ASHBURN, Va., May 02, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company intends to release its first quarter 2023 financial results after the market closes on Monday, May 8, 2023. The Company will also host a conference call and webcast on May 9, 2023, at 8:30 am ET, to discuss the Company's first quarter 2023 financial results and to provide a corporate update. The live call can be accessed by dialing 1-877-270-2148 (domestic) or 1-412-902-6510 (international). The live and archived webcast of the call will be available on th

ASHBURN, Va., March 02, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company intends to release its 2022 fourth quarter and year-end financial results after the market closes on Wednesday, March 8, 2023. The Company will host a conference call and webcast at 8:30am ET on Thursday, March 9, 2023. The call will include a discussion of fourth quarter 2022 and year-end results. The live call can be accessed by dialing 1-877-270-2148 (domestic) or 1-412-902-6510 (international). The live and archived webcast of the call will also be

ASHBURN, Va., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today updated timing for its third quarter 2022 business update conference call and webcast. The conference call and webcast will now take place at 10:00am ET on Thursday November 10th, 2022. The third quarter 2022 financial results will be reported before the open of the financial markets on the same day, Thursday November 10, 2022. The live call can be accessed by dialing 1-877-270-2148 (domestic) or 1-412-902-6510 (international). The live and archived webcast of the call w

ASHBURN, Va., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that its third quarter 2022 financial results will be reported on Thursday, November 10, 2022 before the open of the financial markets. Management will also host a webcast and conference call on November 10, 2022 at 8:30 a.m. ET to discuss the results and provide a corporate update. The live call can be accessed by dialing 1-877-270-2148 (domestic) or 1-412-902-6510 (international). The live and archived webcast of the call will be available on the Quoin Pharmaceuticals

ASHBURN, Va., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that its second quarter 2022 financial results will be reported on Thursday, August 18, 2022 before the open of the financial markets. Management will also host a webcast and conference call on August 18, 2022 at 8:30 a.m. ET to discuss the results and provide a corporate update. The live call can also be accessed by dialing 1-877-270-2148 (domestic) or 1-412-902-6510 (international). The live and archived webcast of the call may be accessed on the Quoin Phar